BETA DRUGS Q2 FY27 : NET PROFIT UP 58% AT ₹19 CR (YOY), UP 17% (QOQ)

REVENUE UP 33% AT ₹137 CR (YOY), UP 10% (QOQ) EBITDA UP 42% AT ₹30 CR (YOY), UP 11% (QOQ) MARGINS AT 22.0% VS 20.6% (YOY), 21.8% (QOQ)

BETA DRUGS LIMITED